ERAS Erasca, Inc.
Stock · NasdaqGS · United States · Healthcare · US29479A1088
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Erasca, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:41. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Nov 2026 16:00 | -0.13 | — | — | Upcoming |
| 12 Aug 2026 16:00 | -0.11 | — | — | — |
| 11 May 2026 16:00 | -0.23 | -0.60 | -166.0% | Miss |
| 12 Mar 2026 16:00 | -0.11 | -0.10 | +6.0% | Beat |
| 12 Nov 2025 16:00 | -0.11 | -0.11 | -4.5% | Miss |
| 12 Aug 2025 16:00 | -0.11 | -0.12 | -5.9% | Miss |
| 13 May 2025 16:00 | -0.13 | -0.11 | +13.1% | Beat |
| 20 Mar 2025 16:00 | -0.13 | -0.11 | +13.5% | Beat |
| 12 Nov 2024 16:00 | -0.17 | -0.11 | +34.2% | Beat |
| 12 Aug 2024 16:00 | -0.19 | -0.29 | -56.6% | Miss |
| 08 May 2024 16:00 | -0.20 | -0.23 | -16.8% | Miss |
| 27 Mar 2024 16:00 | -0.21 | -0.20 | +6.1% | Beat |
| 09 Nov 2023 16:00 | -0.22 | -0.20 | +9.1% | Beat |
| 10 Aug 2023 16:00 | -0.24 | -0.21 | +11.0% | Beat |
| 15 May 2023 16:00 | -0.31 | -0.22 | +30.0% | Beat |
| 23 Mar 2023 16:00 | -0.32 | -1.06 | -231.6% | Miss |
| 09 Nov 2022 16:00 | -0.31 | -0.29 | +6.5% | Beat |
| 11 Aug 2022 16:00 | -0.33 | -0.30 | +8.1% | Beat |
| 12 May 2022 16:00 | -0.30 | -0.31 | -3.2% | Miss |
| 24 Mar 2022 16:00 | -0.35 | -0.26 | +24.8% | Beat |
| 10 Nov 2021 16:00 | -0.64 | -0.46 | +27.7% | Beat |
| 26 Aug 2021 16:00 | -0.82 | -1.20 | -46.3% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 0 | — | -124.5M | — | -0.44 | +36.2% | -105.1M |
| 2024 | 0 | — | -161.7M | — | -0.69 | +16.9% | -132M |
| 2023 | 0 | — | -125M | — | -0.83 | +58.3% | -123M |
| 2022 | 0 | — | -242.8M | — | -1.99 | — | -119.8M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 18 Dec 2023 – 22 Dec 2023 | 1.88 | 2.12 | 1.81 | 2.11 | +12.83% | 6,318,800 | |
| 11 Dec 2023 – 15 Dec 2023 | 1.89 | 2.15 | 1.78 | 1.87 | 0.00% | 8,661,700 | |
| 04 Dec 2023 – 08 Dec 2023 | 1.65 | 1.95 | 1.63 | 1.87 | +11.98% | 20,390,800 | |
| 27 Nov 2023 – 01 Dec 2023 | 2.33 | 2.33 | 1.51 | 1.67 | -28.33% | 9,411,600 | |
| 20 Nov 2023 – 24 Nov 2023 | 2.27 | 2.38 | 2.14 | 2.33 | +1.75% | 929,800 | |
| 13 Nov 2023 – 17 Nov 2023 | 2.01 | 2.41 | 1.90 | 2.29 | +13.93% | 2,486,900 | |
| 06 Nov 2023 – 10 Nov 2023 | 2.42 | 2.51 | 1.95 | 2.01 | -16.94% | 2,009,700 | |
| 30 Oct 2023 – 03 Nov 2023 | 2.01 | 2.55 | 1.98 | 2.42 | +21.61% | 3,117,500 | |
| 23 Oct 2023 – 27 Oct 2023 | 2.21 | 2.39 | 1.97 | 1.99 | -10.36% | 2,566,100 | |
| 16 Oct 2023 – 20 Oct 2023 | 2.38 | 2.47 | 2.16 | 2.22 | -5.13% | 3,490,800 | |
| 09 Oct 2023 – 13 Oct 2023 | 2.17 | 2.79 | 2.13 | 2.34 | +5.88% | 5,809,800 | |
| 02 Oct 2023 – 06 Oct 2023 | 1.96 | 2.25 | 1.82 | 2.21 | +12.18% | 4,935,600 | |
| 25 Sep 2023 – 29 Sep 2023 | 2.24 | 2.24 | 1.96 | 1.97 | -12.44% | 2,294,500 | |
| 18 Sep 2023 – 22 Sep 2023 | 2.58 | 2.58 | 2.24 | 2.25 | -12.79% | 3,961,600 | |
| 11 Sep 2023 – 15 Sep 2023 | 2.64 | 2.72 | 2.49 | 2.58 | -1.15% | 4,094,800 | |
| 05 Sep 2023 – 08 Sep 2023 | 2.59 | 2.69 | 2.51 | 2.61 | +0.77% | 1,352,800 | |
| 28 Aug 2023 – 01 Sep 2023 | 2.65 | 2.68 | 2.50 | 2.59 | -1.15% | 1,614,600 | |
| 21 Aug 2023 – 25 Aug 2023 | 2.51 | 2.70 | 2.47 | 2.62 | +4.38% | 1,748,100 | |
| 14 Aug 2023 – 18 Aug 2023 | 2.93 | 2.93 | 2.47 | 2.51 | -13.75% | 2,980,500 | |
| 07 Aug 2023 – 11 Aug 2023 | 2.61 | 2.97 | 2.50 | 2.91 | +11.49% | 3,238,600 | |
| 31 Jul 2023 – 04 Aug 2023 | 2.60 | 2.71 | 2.55 | 2.61 | +0.38% | 2,536,200 | |
| 24 Jul 2023 – 28 Jul 2023 | 2.63 | 2.64 | 2.45 | 2.60 | -1.14% | 1,905,600 | |
| 17 Jul 2023 – 21 Jul 2023 | 2.63 | 2.75 | 2.55 | 2.63 | 0.00% | 1,523,400 | |
| 10 Jul 2023 – 14 Jul 2023 | 2.74 | 2.91 | 2.56 | 2.63 | -4.01% | 2,230,300 | |
| 03 Jul 2023 – 07 Jul 2023 | 2.73 | 2.84 | 2.65 | 2.74 | -0.72% | 1,545,700 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 (opens in a new tab) 04 Nov 2026 13:30
- Erasca to Present at Upcoming Conferences in November (opens in a new tab) 03 Nov 2026 13:00
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 13.27 USD
- Market cap
- 5.0B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 8.8 / 25 No figures for this part: it counts as a cautious 35%. | — |
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 0.0 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 0.0 / 15 | — |
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 70% of the figures (grade C). Warnings take 6 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -23.12× | Weak | 14.98× |
| Price / book | 12.44× | Weak | 3.94× |
| EV / EBITDA | -29.9× | Weak | 12.96× |
| Free cash flow yield | -4.2% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 0% | Weak | 59.2% |
| Operating margin | 0% | Weak | 7.4% |
| Net margin | 0% | Weak | 3.4% |
| Return on equity | -78.2% | Weak | 5.7% |
| Return on assets | -21.4% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.12× | Good | 0.46× |
| Current ratio | 8.29× | Good | 2.35× |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow ERAS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.